Paul Hud­son spells out new $6.15B tech­nol­o­gy play as Sanofi goes drug hunt­ing in on­col­o­gy, im­munol­o­gy

Sanofi now has an­oth­er pow­er­ful weapon in its ar­se­nal to de­ploy against a wide va­ri­ety of tar­gets across on­col­o­gy, im­munol­o­gy and in­flam­ma­tion.

Ty­ing the knot …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER